2015
Immunotherapy and targeted therapy for cervical cancer: an update
Menderes G, Black J, Schwab CL, Santin AD. Immunotherapy and targeted therapy for cervical cancer: an update. Expert Review Of Anticancer Therapy 2015, 16: 83-98. PMID: 26568261, DOI: 10.1586/14737140.2016.1121108.Peer-Reviewed Original ResearchConceptsCervical cancer patientsCervical cancerCancer patientsImmune check pointsUse of immunotherapyMetastatic cervical cancerPrognosis of patientsActionable driver mutationsTyrosine kinase inhibitorsImmune system interactionsImmunotherapy studiesMedian survivalAngiogenesis inhibitorsChemotherapeutic drugsPatientsDriver mutationsKinase inhibitorsNew therapeuticsCancerNext-generation sequencingImmunotherapyTherapyGeneration sequencingInhibitorsPrognosis
2007
Metastatic Uterine Leiomyosarcoma Regression Using an Aromatase Inhibitor
Hardman MP, Roman JJ, Burnett AF, Santin AD. Metastatic Uterine Leiomyosarcoma Regression Using an Aromatase Inhibitor. Obstetrics And Gynecology 2007, 110: 518-520. PMID: 17666649, DOI: 10.1097/01.aog.0000267533.56546.c2.Peer-Reviewed Original ResearchConceptsUterine leiomyosarcomaAromatase inhibitorsTotal abdominal hysterectomyUterine leiomyosarcoma metastaticEstrogen receptor positivityPrimary uterine leiomyosarcomaMetastatic tumor nodulesAdjuvant platinumAnastrozole dailyLeiomyosarcoma metastaticAbdominal hysterectomyObjective responseReceptor positivityTumor depositsChemotherapeutic optionsDoxorubicin chemotherapySerial imagingTumor regressionTumor nodulesLeiomyosarcomaLungInhibitorsHysterectomyNulligravidaMetastatic